Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%

Thumbnail

View/Open

Date

2020

Author

Reid, Michelle
Balcı, Serdar
Bağcı, Pelin
Saka, Burcu
Pehlivanoğlu, Burçin
Erbarut Seven, İpek
Baştürk, Olca
Adsay, N. Volkan

Metadata

Show full item record

Citation

Reid, M., Balcı, S., Bağcı, P., Saka, B., Pehlivanoğlu, B., Erbarut Seven, İ. ... Adsay, N. V. (2020). Is it justifiable to move the grade-1 ki67 index cut-off from 3% to 5% for pancreatic neuroendocrine tumors as has been proposed? The cases that fall to 3-5% category have clinicopathologic characteristics closer to those > 5%. 109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP) içinde (1673-1673. ss.). Los Angeles, CA, February 29-March 05, 2020.

Abstract

Background: Grading of linear parameters into meaningful (clinically relevant) clusters is a well-known challenge. Recently several groupshave proposed to change the Ki67 index cut-off for grade 1 (G1) category for PanNETs from < 3% to < 5%. This proposal presupposes thatthe cases with Ki67 index of 3-5% are NOT clinically different than the 0-3% group and thus can be lumped together with the current G1 (0-3% cases), instead of their current home in the G2 category (> 3%).

Source

109th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP)

Volume

33

Issue

Supplement: 2

URI

https://hdl.handle.net/20.500.12511/5129

Collections